
Sigilon Therapeutics Inc is a biotechnology business based in the US. Sigilon Therapeutics Inc shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics Inc employs 66 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Sigilon Therapeutics Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SGTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Sigilon Therapeutics Inc stock price (NASDAQ: SGTX)
Use our graph to track the performance of SGTX stocks over time.Sigilon Therapeutics Inc shares at a glance
Latest market close | $0.77 |
---|---|
52-week range | $0.73 - $10.54 |
50-day moving average | $0.93 |
200-day moving average | $2.60 |
Wall St. target price | $3.95 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.25 |
Buy Sigilon Therapeutics Inc shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sigilon Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sigilon Therapeutics Inc price performance over time
Historical closes compared with the close of $0.765 from 2022-07-01
1 week (2022-06-28) | -7.83% |
---|---|
1 month (2022-06-06) | -12.27% |
3 months (2022-04-06) | -49.67% |
6 months (2022-01-06) | -69.64% |
1 year (2021-07-06) | -92.14% |
---|---|
2 years (2020-07-02) | N/A |
3 years (2019-07-02) | N/A |
5 years (2017-07-02) | N/A |
Sigilon Therapeutics Inc financials
Revenue TTM | $9.8 million |
---|---|
Gross profit TTM | $-54,270,000 |
Return on assets TTM | -26.23% |
Return on equity TTM | -74.58% |
Profit margin | 0% |
Book value | $1.99 |
Market capitalisation | $24.8 million |
TTM: trailing 12 months
Sigilon Therapeutics Inc share dividends
We're not expecting Sigilon Therapeutics Inc to pay a dividend over the next 12 months.
Sigilon Therapeutics Inc overview
Sigilon Therapeutics, Inc. , a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc.
Frequently asked questions
What percentage of Sigilon Therapeutics Inc is owned by insiders or institutions?Currently 21.832% of Sigilon Therapeutics Inc shares are held by insiders and 56.425% by institutions. How many people work for Sigilon Therapeutics Inc?
Latest data suggests 66 work at Sigilon Therapeutics Inc. When does the fiscal year end for Sigilon Therapeutics Inc?
Sigilon Therapeutics Inc's fiscal year ends in December. Where is Sigilon Therapeutics Inc based?
Sigilon Therapeutics Inc's address is: 100 Binney Street, Cambridge, MA, United States, 02142 What is Sigilon Therapeutics Inc's ISIN number?
Sigilon Therapeutics Inc's international securities identification number is: US82657L1070
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert